| Title |
β-Secretase as a Therapeutic Target for Alzheimer's Disease
|
|---|---|
| Published in |
Neurotherapeutics, July 2008
|
| DOI | 10.1016/j.nurt.2008.05.007 |
| Pubmed ID | |
| Authors |
Arun K. Ghosh, Sandra Gemma, Jordan Tang |
| Abstract |
beta-Secretase (memapsin 2, BACE1) is an attractive target for the development of inhibitor drugs to treat Alzheimer's disease (AD). Not only does this protease function at the first step in the pathway leading to the production of amyloid-beta (Abeta), its gene deletion produces only mild phenotypes. In addition, beta-secretase is an aspartic protease whose mechanism and inhibition are well known. The development of beta-secretase inhibitors, actively pursued over the last seven years, has been slow, due to the difficulty in combining the required properties in a single inhibitor molecule. Steady progress in this field, however, has brought about inhibitors that contain many targeted characteristics. In this review, we describe the strategy of structure-based inhibitor evolution in the development of beta-secretase inhibitor drug. The current status of the field offers grounds for some optimism, in that beta-secretase inhibitors have been shown to reduce brain Abeta and to rescue the cognitive decline in transgenic AD mice, and an orally available beta-secretase inhibitor drug candidate is in clinical trial. With this knowledge base, it seems reasonable to expect that more drug candidates will be tested in human, and then successful disease-modifying drugs may ultimately emerge from this target. |
Mendeley readers
The data shown below were compiled from readership statistics for 147 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 1% |
| Italy | 1 | <1% |
| Hong Kong | 1 | <1% |
| Germany | 1 | <1% |
| Belgium | 1 | <1% |
| Canada | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 138 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 30 | 20% |
| Researcher | 28 | 19% |
| Student > Master | 25 | 17% |
| Student > Bachelor | 22 | 15% |
| Student > Doctoral Student | 6 | 4% |
| Other | 22 | 15% |
| Unknown | 14 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 37 | 25% |
| Chemistry | 32 | 22% |
| Biochemistry, Genetics and Molecular Biology | 16 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 11% |
| Medicine and Dentistry | 7 | 5% |
| Other | 18 | 12% |
| Unknown | 21 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2023.
All research outputs
#2,107,477
of 25,373,627 outputs
Outputs from Neurotherapeutics
#185
of 1,308 outputs
Outputs of similar age
#5,649
of 95,609 outputs
Outputs of similar age from Neurotherapeutics
#3
of 11 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,609 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.